Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects.
Front Pharmacol
; 13: 970324, 2022.
Article
in En
| MEDLINE
| ID: mdl-36120311
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
Front Pharmacol
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: